Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships

References

• Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262–1279.e2. doi:10.1053/j.gastro.2016.02.032.
   Web of Science ®Google Scholar
• Akehurst RL, Brazier JE, Mathers N, O’keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20(7):455–15. doi:10.2165/00019053-200220070-00003.
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–21 e4. doi:10.1016/j.cgh.2012.02.029.
   PubMed Web of Science ®Google Scholar
• Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021;131(7–8):709–715. doi:10.20452/pamw.16067.
   PubMedGoogle Scholar
• Kim JH, Lin E, Pimentel M. Biomarkers of irritable bowel syndrome. J Neurogastroenterol Motil. 2017;23(1):20–26. doi:10.5056/jnm16135.
   PubMed Web of Science ®Google Scholar
• Barbara G, Cremon C, De Giorgio R, Dothel G, Zecchi L, Bellacosa L, Carini G, Stanghellini V, Corinaldesi R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep. 2011;13(4):308–315. doi:10.1007/s11894-011-0195-7.
   PubMedGoogle Scholar
• Fagoonee S, Pellicano R. Does the microbiota play a pivotal role in the pathogenesis of irritable bowel syndrome? J Clin Med. 2019;8(11):1808. doi:10.3390/jcm8111808.
   PubMed Web of Science ®Google Scholar
• Mckernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther. 2011;33(9):1045–1052. doi:10.1111/j.1365-2036.2011.04624.x.
   PubMed Web of Science ®Google Scholar
• Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol. 2015;6:620. doi:10.3389/fimmu.2015.00620.
   PubMed Web of Science ®Google Scholar
• Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP. Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases. Lab Invest. 1989;60:847–851.
   PubMed Web of Science ®Google Scholar
• Arevalo F, Aragon V, Montes P, Guzmán E, Monge E. Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome. Rev Gastroenterol Peru. 2011;31:315–318.
   PubMedGoogle Scholar
• Guilarte M, Santos J, De Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203–209. doi:10.1136/gut.2006.100594.
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–811. doi:10.1136/gut.47.6.804.
   PubMed Web of Science ®Google Scholar
• Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiological Reviews. 1997;77(4):1033–1079. doi:10.1152/physrev.1997.77.4.1033.
   PubMed Web of Science ®Google Scholar
• Wang LH. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53(8):1096–1101. doi:10.1136/gut.2003.021154.
   PubMed Web of Science ®Google Scholar
• Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137(4):1425–1434. doi:10.1053/j.gastro.2009.07.005.
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37. doi:10.1053/j.gastro.2006.11.039.
   PubMed Web of Science ®Google Scholar
• Merluzzi S, Frossi B, Gri G, Parusso S, Tripodo C, Pucillo C. Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells. Blood. 2010;115(14):2810–2817. doi:10.1182/blood-2009-10-250126.
   PubMed Web of Science ®Google Scholar
• Chirdo FG, Millington OR, Beacock-Sharp H, Mowat A. Immunomodulatory dendritic cells in intestinal lamina propria. Eur J Immunol. 2005;35(6):1831–1840. doi:10.1002/eji.200425882.
   PubMed Web of Science ®Google Scholar
• Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129(1):50–65. doi:10.1053/j.gastro.2005.05.013.
   PubMed Web of Science ®Google Scholar
• Psarras A, Antanaviciute A, Alase A, Carr I, Wittmann M, Emery P, Tsokos GC, Vital EM. TNF-α regulates human plasmacytoid dendritic cells by suppressing IFN-α production and enhancing T cell activation. J Immunol. 2021;206(4):785–796. doi:10.4049/jimmunol.1901358.
   PubMed Web of Science ®Google Scholar
• Linan-Rico A, Ochoa-Cortes F, Zuleta-Alarcon A, Alhaj M, Tili E, Enneking J, Harzman A, Grants I, Bergese S, Christofi FL. UTP – gated signaling pathways of 5-HT release from BON cells as a model of human enterochromaffin cells. Front Pharmacol. 2017;8:429. doi:10.3389/fphar.2017.00429.
   PubMed Web of Science ®Google Scholar
• Mishima Y, Ishihara S. Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome. Int J Mol Sci. 2021;22(19):10235. doi:10.3390/ijms221910235.
   PubMed Web of Science ®Google Scholar
• Tao E, Zhu Z, Hu C, Long G, Chen B, Guo R, Fang M, Jiang M. Potential roles of enterochromaffin cells in early life stress-induced irritable bowel syndrome. Front Cell Neurosci. 2022;16:837166. doi:10.3389/fncel.2022.837166.
   PubMed Web of Science ®Google Scholar
• O’Sullivan M, Clayton N, Breslin NP. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12(5):449–457. doi:10.1046/j.1365-2982.2000.00221.x.
   PubMed Web of Science ®Google Scholar
• Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjövall H, Simrén M. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(5):1205–1212. doi:10.1038/ajg.2009.116.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16(4):363–373. doi:10.5056/jnm.2010.16.4.363.
   PubMedGoogle Scholar
• Chen ZY, Zhang XW, Yu L, Hua R, Zhao XP, Qin X, Zhang YM. Spinal toll-like receptor 4-mediated signalling pathway contributes to visceral hypersensitivity induced by neonatal colonic irritation in rats. Eur J Pain. 2015;19(2):176–186. doi:10.1002/ejp.534.
   PubMed Web of Science ®Google Scholar
• Nozu T, Miyagishi S, Ishioh M, Takakusaki K, Okumura T. Peripheral apelin mediates visceral hypersensitivity and impaired gut barrier in a rat irritable bowel syndrome model. Neuropeptides. 2022;94:102248. doi:10.1016/j.npep.2022.102248.
   PubMed Web of Science ®Google Scholar
• Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Déchelotte P, Coëffier M, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PloS One. 2012;7(8):e42777. doi:10.1371/journal.pone.0042777.
   PubMed Web of Science ®Google Scholar
• Brint EK, Macsharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011;106(2):329–336. doi:10.1038/ajg.2010.438.
   PubMed Web of Science ®Google Scholar
• Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, Marasco G, Stanghellini V. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Front Nutr. 2021;8:718356. doi:10.3389/fnut.2021.718356.
   PubMed Web of Science ®Google Scholar
• Li M, Oshima T, Ito C, Yamada M, Tomita T, Fukui H, Miwa H. Glutamine blocks interleukin-13-induced intestinal epithelial barrier dysfunction. Digestion. 2021;102(2):170–179. doi:10.1159/000502953.
   PubMed Web of Science ®Google Scholar
• Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075–1083. doi:10.1016/j.cgh.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Hasler WL, Grabauskas G, Singh P, Owyang C. Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome. Neurogastroenterol Motil. 2022;34(7):e14339. doi:10.1111/nmo.14339.
   PubMed Web of Science ®Google Scholar
• Wilcz-VIllega E, Mcclean S, O’Sullivan M. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS. Neurogastroenterol Motil. 2014;26(3):316–325. doi:10.1111/nmo.12262.
   PubMed Web of Science ®Google Scholar
• Piche T. Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302. doi:10.1111/nmo.12315.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1–2):41–46. doi:10.1016/j.pain.2009.06.017.
   PubMed Web of Science ®Google Scholar
• Lee H, Park JH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Chae SW. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J Neurogastroenterol Motil. 2013;19(2):244–250. doi:10.5056/jnm.2013.19.2.244.
   PubMed Web of Science ®Google Scholar
• Mujagic Z, Ludidi S, Keszthelyi D, Hesselink MAM, Kruimel JW, Lenaerts K, Hanssen NMJ, Conchillo JM, Jonkers DMAE, Masclee AAM, et al. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther. 2014;40(3):288–297. doi:10.1111/apt.12829.
   PubMed Web of Science ®Google Scholar
• Martinez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, Alonso C, Guilarte M, Guilá M, de Torres I, Azpiroz F, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62(8):1160–1168. doi:10.1136/gutjnl-2012-302093.
   PubMed Web of Science ®Google Scholar
• Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL. Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms. Nutrients. 2021;13(5):1506. doi:10.3390/nu13051506.
   PubMed Web of Science ®Google Scholar
• Hou Q, Huang Y, Zhu S, Li P, Chen X, Hou Z, Liu F. MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1. Cell Physiol Biochem. 2017;44(6):2256–2268. doi:10.1159/000486059.
   PubMedGoogle Scholar
• Xu XJ, Zhang YL, Liu L, Pan L, Yao SK. Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. Aliment Pharmacol Ther. 2017;45(1):100–114. doi:10.1111/apt.13848.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–230. doi:10.1038/nature11550.
   PubMed Web of Science ®Google Scholar
• Kogut MH, Lee A, Santin E. Microbiome and pathogen interaction with the immune system. Poult Sci. 2020;99(4):1906–1913. doi:10.1016/j.psj.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. WJG. 2019;25(33):4814–4834. doi:10.3748/wjg.v25.i33.4814.
   PubMed Web of Science ®Google Scholar
• Mou Y, Du Y, Zhou L, Yue J, Hu X, Liu Y, Chen S, Lin X, Zhang G, Xiao H, et al. Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging. Front Immunol. 2022;13:796288. doi:10.3389/fimmu.2022.796288.
   PubMed Web of Science ®Google Scholar
• Black CJ, Ford AC. Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. Med J Aust. 2018;209(2):86–91. doi:10.5694/mja18.00241.
   PubMed Web of Science ®Google Scholar
• Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279–1286.
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttila T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373–382. doi:10.1111/j.1572-0241.2005.40312.x.
   PubMed Web of Science ®Google Scholar
• Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017;312(1):G52–G62. doi:10.1152/ajpgi.00338.2016.
   PubMed Web of Science ®Google Scholar
• Shukla R, Ghoshal U, Ranjan P, Ghoshal UC. Expression of toll-like receptors, pro-, and anti-inflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: the evidence for its micro-organic basis. J Neurogastroenterol Motil. 2018;24(4):628–642. doi:10.5056/jnm18130.
   PubMed Web of Science ®Google Scholar
• Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. 2019;16(1):53. doi:10.1186/s12974-019-1434-3.
   PubMed Web of Science ®Google Scholar
• Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163–173. doi:10.1038/nrgastro.2010.4.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil. 2008;20(10):1110–1118. doi:10.1111/j.1365-2982.2008.01166.x.
   PubMed Web of Science ®Google Scholar
• Guven IE, Baspinar B, Atalay R. Relationship between systemic immune-inflammation index and irritable bowel syndrome. Turk J Gastroenterol. 2022;33(1):30–34. doi:10.5152/tjg.2021.21321.
   PubMed Web of Science ®Google Scholar
• Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2013;305(8):G529–41. doi:10.1152/ajpgi.00207.2012.
   PubMed Web of Science ®Google Scholar
• Dong LW, Ma ZC, Fu J, Huang BL, Liu FJ, Sun D, Lan C. Upregulated adenosine 2A receptor accelerates post-infectious irritable bowel syndrome by promoting CD4+ T cells’ T helper 17 polarization. World J Gastroenterol. 2022;28(25):2955–2967. doi:10.3748/wjg.v28.i25.2955.
   PubMed Web of Science ®Google Scholar
• Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). JIR. 2018;11:345–349. doi:10.2147/JIR.S174982.
   Google Scholar
• Talley NJ. What causes functional gastrointestinal disorders? A proposed disease model. Am J Gastroenterol. 2020;115(1):41–48. doi:10.14309/ajg.0000000000000485.
   PubMed Web of Science ®Google Scholar
• Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36(11–12):1009–1031. doi:10.1111/apt.12080.
   PubMed Web of Science ®Google Scholar
• Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104(2):392–400. doi:10.1038/ajg.2008.94.
   PubMed Web of Science ®Google Scholar
• Shulman RJ, Devaraj S, Heitkemper M. Activation of the innate immune system in children with irritable bowel syndrome evidenced by increased fecal human beta-defensin-2. Clin Gastroenterol Hepatol. 2021;19(10):2121–2127. doi:10.1016/j.cgh.2020.09.034.
   PubMed Web of Science ®Google Scholar
• Teicher MH. Scars that won’t heal: the neurobiology of child abuse. Sci Am. 2002;286(3):68–75. doi:10.1038/scientificamerican0302-68.
   PubMed Web of Science ®Google Scholar
• Saridjan NS, Huizink AC, Koetsier JA, Jaddoe VW, Mackenbach JP, Hofman A, Kirschbaum C, Verhulst FC, Tiemeier H. Do social disadvantage and early family adversity affect the diurnal cortisol rhythm in infants? The generation R study. Horm Behav. 2010;57(2):247–254. doi:10.1016/j.yhbeh.2009.12.001.
   PubMed Web of Science ®Google Scholar
• Videlock EJ, Adeyemo M, Licudine A, Hirano M, Ohning G, Mayer M, Mayer EA, Chang L. Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology. 2009;137(6):1954–1962. doi:10.1053/j.gastro.2009.08.058.
   PubMed Web of Science ®Google Scholar
• Frodl T, Reinhold E, Koutsouleris N, Reiser M, Meisenzahl EM. Interaction of childhood stress with hippocampus and prefrontal cortex volume reduction in major depression. J Psychiatr Res. 2010;44(13):799–807. doi:10.1016/j.jpsychires.2010.01.006.
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie–Doyle S, Smith E, Drew P, Talley NJ, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132(3):913–920. doi:10.1053/j.gastro.2007.01.046.
   PubMed Web of Science ®Google Scholar
• Bluthe RM, Michaud B, Kelley KW, Dantzer R. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport. 1996;7(15):2823–2827. doi:10.1097/00001756-199611040-00083.
   PubMed Web of Science ®Google Scholar
• Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018;12:49. doi:10.3389/fnins.2018.00049.
   PubMed Web of Science ®Google Scholar
• Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther. 2007;116(2):207–235. doi:10.1016/j.pharmthera.2007.06.008.
   PubMed Web of Science ®Google Scholar
• Yu L, Li Y. Involvement of intestinal enteroendocrine cells in neurological and psychiatric disorders. Biomedicines. 2022;10(10):2577. doi:10.3390/biomedicines10102577.
   PubMed Web of Science ®Google Scholar
• Huh JR, Veiga-Fernandes H. Neuroimmune circuits in inter-organ communication. Nat Rev Immunol. 2020;20(4):217–228. doi:10.1038/s41577-019-0247-z.
   PubMed Web of Science ®Google Scholar
• Jung Y, Rothenberg ME. Roles and regulation of gastrointestinal eosinophils in immunity and disease. The J Immunol. 2014;193(3):999–1005. doi:10.4049/jimmunol.1400413.
   PubMed Web of Science ®Google Scholar
• Salvo-Romero E, Rodino-Janeiro BK, Albert-Bayo M, Lobo B, Santos J, Farré R, Martinez C, Vicario M. Eosinophils in the gastrointestinal tract: key contributors to neuro-immune crosstalk and potential implications in disorders of brain-gut interaction. Cells. 2022;11(10):1644. doi:10.3390/cells11101644.
   PubMed Web of Science ®Google Scholar
• Yan BM, Shaffer EA. Primary eosinophilic disorders of the gastrointestinal tract. Gut. 2009;58(5):721–732. doi:10.1136/gut.2008.165894.
   PubMed Web of Science ®Google Scholar
• Rojas OL, Probstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, Lee DSW, Galicia G, Ramaglia V, Ward LA, et al. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10. Cell. 2019;177(2):492–493. doi:10.1016/j.cell.2019.03.037.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick Z, Frazer G, Ferro A, Clare S, Bouladoux N, Ferdinand J, Tuong ZK, Negro-Demontel ML, Kumar N, Suchanek O, et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature. 2020;587(7834):472–476. doi:10.1038/s41586-020-2886-4.
   PubMed Web of Science ®Google Scholar
• Galley JD, Bailey MT. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes. 2014;5(3):390–396. doi:10.4161/gmic.28683.
   PubMed Web of Science ®Google Scholar
• Hemmings SMJ, Malan-Muller S, Van Den Heuvel LL, Demmitt BA, Stanislawski MA, Smith DG, Bohr AD, Stamper CE, Hyde ER, Morton JT, et al. The microbiome in posttraumatic stress disorder and trauma-exposed controls: an exploratory study. Psychosom Med. 2017;79(8):936–946. doi:10.1097/PSY.0000000000000512.
   PubMed Web of Science ®Google Scholar
• Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203–209.
   PubMed Web of Science ®Google Scholar
• Borre YE, O’keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014;20(9):509–518. doi:10.1016/j.molmed.2014.05.002.
   PubMed Web of Science ®Google Scholar
• Leserman J, Drossman DA. Relationship of abuse history to functional gastrointestinal disorders and symptoms: some possible mediating mechanisms. Trauma Violence Abuse. 2007;8(3):331–343. doi:10.1177/1524838007303240.
   PubMed Web of Science ®Google Scholar
• Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, Mayer M, Vuong T, Hirano M, Naliboff BD, et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil. 2009;21(2):149–159. doi:10.1111/j.1365-2982.2008.01171.x.
   PubMed Web of Science ®Google Scholar
• Agirman G, Yu KB, Hsiao EY. Signaling inflammation across the gut-brain axis. Sci. 2021;374(6571):1087–1092. doi:10.1126/science.abi6087.
   PubMed Web of Science ®Google Scholar
• Cryan JF, O’riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TF, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877–2013. doi:10.1152/physrev.00018.2018.
   PubMed Web of Science ®Google Scholar
• Xu C, Lee SK, Zhang D, Frenette PS. The gut microbiome regulates psychological-stress-induced inflammation. Immunity. 2020;53(2):417–428.e4. doi:10.1016/j.immuni.2020.06.025.
   PubMed Web of Science ®Google Scholar
• Welcome MO, Mastorakis NE. Stress-induced blood brain barrier disruption: molecular mechanisms and signaling pathways. Pharmacol Res. 2020;157:104769. doi:10.1016/j.phrs.2020.104769.
   PubMed Web of Science ®Google Scholar
• Vanuytsel T, Van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S, Houben E, Salim Rasoel S, Tόth J, Holvoet L, Farré R, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63(8):1293–1299. doi:10.1136/gutjnl-2013-305690.
   PubMed Web of Science ®Google Scholar
• Fukudo S. Stress and visceral pain: focusing on irritable bowel syndrome. Pain. 2013;154(Suppl 1):S63–S70. doi:10.1016/j.pain.2013.09.008.
   PubMedGoogle Scholar
• Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol. 2011;26(Suppl 3):119–121. doi:10.1111/j.1440-1746.2011.06640.x.
   PubMedGoogle Scholar
• Huang ST, Song ZJ, Liu Y, Luo WC, Yin Q, Zhang YM. BNST(AV) (GABA)-PVN(CRF) circuit regulates visceral hypersensitivity induced by maternal separation in Vgat-Cre mice. Front Pharmacol. 2021;12:615202. doi:10.3389/fphar.2021.615202.
   PubMed Web of Science ®Google Scholar
• Song Y, Meng QX, Wu K, Hua R, Song ZJ, Song Y, Qin X, Cao JL, Zhang YM. Disinhibition of PVN-projecting GABAergic neurons in AV region in BNST participates in visceral hypersensitivity in rats. Psychoneuroendocrinology. 2020;117:104690. doi:10.1016/j.psyneuen.2020.104690.
   PubMed Web of Science ®Google Scholar
• El-Salhy M. Recent advances in the diagnosis of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2015;9(9):1161–1174. doi:10.1586/17474124.2015.1067138.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, Norton WF, Weinland S, Dalton C, Leserman J, Bangdiwala SI. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541–550. doi:10.1097/MCG.0b013e318189a7f9.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. doi:10.1056/NEJMoa1004409.
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Raj JP. Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome. Life Sci. 2018;212:176–181. doi:10.1016/j.lfs.2018.10.001.
   PubMed Web of Science ®Google Scholar
• Nee J, Zakari M, Lembo AJ. Novel therapies in IBS-D treatment. Curr Treat Options Gastroenterol. 2015;13(4):432–440. doi:10.1007/s11938-015-0068-5.
   PubMedGoogle Scholar
• Ruepert L, Quartero AO, De Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Of Systematic Reviews. 2011;2011(3). CD003460. doi:10.1002/14651858.CD003460.pub3.
   PubMedGoogle Scholar
• Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56(6):932–941. doi:10.1111/apt.17179.
   PubMed Web of Science ®Google Scholar
• Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114(1):21–39. doi:10.1038/s41395-018-0222-5.
   PubMed Web of Science ®Google Scholar
• Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation 2 ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218–1225. doi:10.1136/gut.2006.110858.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Serra J, Fernandez-Banares F, Mearin F. The low-FODMAP diet for irritable bowel syndrome: lights and shadows. Gastroenterol Hepatol. 2016;39(2):55–65. doi:10.1016/j.gastrohep.2015.07.009.
   PubMed Web of Science ®Google Scholar
• Mearin F, Pena E, Balboa A. Importance of diet in irritable bowel syndrome. Gastroenterol Hepatol. 2014;37(5):302–310. doi:10.1016/j.gastrohep.2013.12.010.
   PubMed Web of Science ®Google Scholar
• Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol. 2010;25(2):252–258. doi:10.1111/j.1440-1746.2009.06149.x.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367–1374. doi:10.1038/ajg.2014.195.
   PubMed Web of Science ®Google Scholar
• Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O’Neill J, Carlson P, Lamsam J, Janzow D, Eckert D, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903–911.e3. doi:10.1053/j.gastro.2013.01.049.
   PubMed Web of Science ®Google Scholar
• Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. WJG. 2015;21(10):3072–3084. doi:10.3748/wjg.v21.i10.3072.
   PubMed Web of Science ®Google Scholar
• Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol. 2016;22(7):2219–2241. doi:10.3748/wjg.v22.i7.2219.
   PubMed Web of Science ®Google Scholar
• Ford AC, Harris LA, Lacy BE, Quigley EM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044–1060. doi:10.1111/apt.15001.
   PubMed Web of Science ®Google Scholar
• Simon E, Calinoiu LF, Mitrea L, Vodnar DC. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients. 2021;13(6):2112. doi:10.3390/nu13062112.
   PubMed Web of Science ®Google Scholar
• Kump P, Hogenauer C. Any future for fecal microbiota transplantation as treatment strategy for inflammatory bowel diseases? Dig Dis. 2016;34(Suppl 1):74–81. doi:10.1159/000447379.
   PubMed Web of Science ®Google Scholar
• Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2019;70(1):335–351. doi:10.1146/annurev-med-111717-122956.
   PubMedGoogle Scholar
• Tkach S, Dorofeyev A, Kuzenko I, Sulaieva O, Falalyeyeva T, Kobyliak N. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: a randomized, clinical trial. Front Med. 2022;9:994911. doi:10.3389/fmed.2022.994911.
   Web of Science ®Google Scholar
• Schmulson M, Bashashati M. Fecal microbiota transfer for bowel disorders: efficacy or hype? Curr Opin Pharmacol. 2018;43:72–80. doi:10.1016/j.coph.2018.08.012.
   PubMed Web of Science ®Google Scholar
• Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759–6773. doi:10.3748/wjg.v20.i22.6759.
   PubMed Web of Science ®Google Scholar
• Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018;60(4):213–222. doi:10.23736/S0031-0808.18.03541-3.
   PubMed Web of Science ®Google Scholar
• Wu HG, Jiang B, Zhou EH, Shi Z, Shi DR, Cui YH, Kou ST, Liu HR. Regulatory mechanism of electroacupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP VIP secretion. Dig Dis Sci. 2008;53(6):1644–1651. doi:10.1007/s10620-007-0062-4.
   PubMed Web of Science ®Google Scholar
• Wu HG, Liu HR, Zhang ZA, Zhou EH, Wang XM, Jiang B, Shi Z, Zhou CL, Qi L, Ma XP. Electro-acupuncture relieves visceral sensitivity and decreases hypothalamic corticotropin-releasing hormone levels in a rat model of irritable bowel syndrome. Neurosci Lett. 2009;465(3):235–237. doi:10.1016/j.neulet.2009.09.018.
   PubMed Web of Science ®Google Scholar
• Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology. 2007;15:5–9.
   PubMedGoogle Scholar
• Chu WC, Wu JC, Yew DT, Zhang L, Shi L, Yeung DK, Wang D, Tong RK, Chan Y, Lao L, et al. Does acupuncture therapy alter activation of neural pathway for pain perception in irritable bowel syndrome?: a comparative study of true and sham acupuncture using functional magnetic resonance imaging. J Neurogastroenterol Motil. 2012;18(3):305–316. doi:10.5056/jnm.2012.18.3.305.
   PubMed Web of Science ®Google Scholar
• Guo J, Yang L, He J, Yang Z. Comparison of therapeutic effects of different acupuncture and moxibustion therapies on irritable bowel syndrome: a protocol for systematic review and network meta-analysis. Medicine (Baltimore). 2021;100:e26920.
   PubMed Web of Science ®Google Scholar
• Jacobs JP, Gupta A, Bhatt RR, Brawer J, Gao K, Tillisch K, Lagishetty V, Firth R, Gudleski GD, Ellingson BM, et al. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome. 2021;9(1):236.
   PubMed Web of Science ®Google Scholar